Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma
VA Chow, M Shadman, AK Gopal - Blood, The Journal of the …, 2018 - ashpublications.org
Chimeric antigen receptor T cells demonstrate efficacy in B-cell malignancies, leading to US
Food and Drug Administration approval of axicabtagene ciloleucel (October 2017) and …
Food and Drug Administration approval of axicabtagene ciloleucel (October 2017) and …
[HTML][HTML] Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma
VA Chow, M Shadman, AK Gopal - Blood, 2018 - Elsevier
Chimeric antigen receptor T cells demonstrate efficacy in B-cell malignancies, leading to US
Food and Drug Administration approval of axicabtagene ciloleucel (October 2017) and …
Food and Drug Administration approval of axicabtagene ciloleucel (October 2017) and …
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma
VA Chow, M Shadman, AK Gopal - Blood, 2018 - pubmed.ncbi.nlm.nih.gov
Chimeric antigen receptor T cells demonstrate efficacy in B-cell malignancies, leading to US
Food and Drug Administration approval of axicabtagene ciloleucel (October 2017) and …
Food and Drug Administration approval of axicabtagene ciloleucel (October 2017) and …
[HTML][HTML] Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma
VA Chow, M Shadman, AK Gopal - Blood, 2018 - ncbi.nlm.nih.gov
Chimeric antigen receptor T cells demonstrate efficacy in B-cell malignancies, leading to US
Food and Drug Administration approval of axicabtagene ciloleucel (October 2017) and …
Food and Drug Administration approval of axicabtagene ciloleucel (October 2017) and …
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
VA Chow, M Shadman, AK Gopal - Blood, 2018 - europepmc.org
Chimeric antigen receptor T cells demonstrate efficacy in B-cell malignancies, leading to US
Food and Drug Administration approval of axicabtagene ciloleucel (October 2017) and …
Food and Drug Administration approval of axicabtagene ciloleucel (October 2017) and …
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma
VA Chow, M Shadman, AK Gopal - Blood, 2018 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Chimeric antigen receptor T cells demonstrate
efficacy in B-cell malignancies, leading to US Food and Drug Administration approval of …
efficacy in B-cell malignancies, leading to US Food and Drug Administration approval of …
Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
VA Chow, M Shadman, AK Gopal - Blood, 2018 - europepmc.org
Chimeric antigen receptor T cells demonstrate efficacy in B-cell malignancies, leading to US
Food and Drug Administration approval of axicabtagene ciloleucel (October 2017) and …
Food and Drug Administration approval of axicabtagene ciloleucel (October 2017) and …